Pinnacle Research Group LLC

1. Eli Lilly and Company $1,271,555 23 payments
2. Amgen Inc. $1,065,838 19 payments
3. GlaxoSmithKline, LLC. $769,826 95 payments
4. Vertex Pharmaceuticals Incorporated $732,216 7 payments
5. Moderna TX, Inc. $679,071 62 payments
6. Regeneron Pharmaceuticals, Inc. $670,128 59 payments
7. Hoffmann-La Roche Limited $648,574 22 payments
8. AstraZeneca UK Limited $548,434 2 payments
9. Pfizer Inc. $522,868 63 payments
10. Novartis Pharmaceuticals Corporation $380,125 4 payments

1. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone Or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity Or Overweight Without Type 2 Diabetes $808,966 3 payments
2. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $785,354 1 payment
3. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $653,279 48 payments
4. Phi Sad Study of Mosun in Patients With Sle $532,888 15 payments
5. a phase I doubl blind,placebo controlled study to evaluate the safety,tolerability and pharmacokinetics of AZD5148 in healthy adults $524,683 1 payment
6. Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) $384,516 2 payments
7. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $328,337 21 payments
8. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants $326,237 27 payments
9. A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study $312,107 17 payments
10. A Phase 1 Randomized Multicenter Doubleblind Sponsor Open Placebocontrolled Single and Multiple Doseescalation Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Pf06835375 in Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis $309,861 15 payments

1. Other $21,950 3 payments
2. Patient care $6,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.